201 HASKINS WAY, SOUTH SAN FRANCISCO, CA
Stock Purchase Agreement with SRX Global Inc. - Cero Therapeutics Holdings
Cero Therapeutics Completes Secured Financing with SRX Global Inc.
Cero Therapeutics Enters Amended Promissory Note for $1.41 Million
Cero Therapeutics Enters $750,000 Convertible Promissory Note Agreement
Cero Therapeutics Issues $400,000 Convertible Promissory Note to Keystone Cap...
Cero Therapeutics Secures $350,000 Convertible Note from Keystone Capital
Cero Therapeutics Issues $750,000 Convertible Promissory Note to Keystone Cap...
FY 2025
Notice of Late Filing for Annual Report
Q3
Notice of Late Filing for Quarterly Report
Q2
Q1
Amended Annual Report
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
PRER14A
Notification Filed by a National Security Exchange
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Schedule 13G - Ownership Report
Submission Upload
Correspondence
Post-Effective Amendment to Registration Statement